• Toremifene: Identity, Mechanism, and Evidence Limits

  2026-10-19

  The APExBIO product description identifies Toremifene as a second-generation selective estrogen-receptor modulator and reports an approximate 1 ± 0.3 μM IC50 for growth inhibition in Ac-1 cells. These claims define a research context, but the available information does not establish an identity-matched primary study, receptor-specific causality, or translational efficacy.

• Jasplakinolide: Documented Actin Mechanism and Scope

  2026-10-18

  Jasplakinolide is described by APExBIO as a membrane-permeable actin polymerization inducer and F-actin stabilizer, with reported binding affinity of approximately 15 nM and stronger activity toward Mg2+-actin than Ca2+-actin. Because no identity-matched research paper is available here, these claims should be treated as supplier-documented properties rather than independently validated study findings; the reported fungicidal and antiproliferative effects remain broad, context-dependent phenotypic descriptions.

• Tetraethylammonium Chloride: Mechanism and Scope

  2026-10-17

  Tetraethylammonium chloride (TEAC) is documented by APExBIO as a quaternary ammonium source and potassium-channel pore blocker. Its strongest supported role in the available material is as a broad mechanistic probe of K⁺-dependent ion conduction, while the supplied evidence does not establish channel-subtype selectivity, quantitative potency, or outcomes from a matched research study.

• TMB Substrate Solution for ELISA: Evidence Scope

  2026-10-16

  APExBIO lists K1131 as a TMB substrate solution for ELISA, but the cited product page provides no description of composition, catalytic partner, readout chemistry, or validation data. The product name supports only a broad interpretation as a downstream assay reagent; it does not establish mechanism, performance, or suitability for any particular assay system.

• Doxycycline: A Proportionate Evidence Overview

  2026-10-16

  APExBIO lists Doxycycline, SKU BA1003, as an orally active tetracycline antibiotic with antimicrobial, metalloproteinase-inhibitory, and antiproliferative activity claims. The available product information supports a documented identity and a broad conceptual research scope, but it does not provide an identity-matched study, quantitative mechanism data, biological models, comparators, or outcome statistics.

• Sucrose: Product Identity and Evidence Boundaries

  2026-10-15

  The APExBIO listing identifies SKU M1202 as sucrose, but the supplied product information contains no description, assay, mechanism, study result, or identity-matched research citation. The defensible interpretation is therefore limited to nominal product identity and a clear account of what cannot be inferred about mechanism, measurement, performance, or applicability.

• Context Changes What AZ505 Results Mean

  2026-10-15

  The reported AZ505 findings in cisplatin-induced chronic kidney disease illustrate why a result cannot be separated from its model, comparator, molecular readout, and provenance. The study supports a connection between SMYD2-associated signaling and cisplatin-related renal injury and fibrosis, but it does not by itself establish broad efficacy across chronic kidney disease, cancer, or human treatment.

• DiscoveryProbe Library Plus: Scope and Evidence

  2026-10-14

  The DiscoveryProbe Bioactive Compound Library Plus is presented by APExBIO as a 5,072-compound research collection organized across multiple biological pathways. Its documented value is primarily that of a broad, formatted screening resource; the available product information does not establish compound-specific mechanisms, quantitative performance, or outcomes from an identity-matched study.

• Hexose Diphosphate and the PEP Evidence Gap

  2026-10-14

  A 2026 Nature Aging study links phosphoenolpyruvate (PEP) with age-related cGAS–STING regulation, but it does not compare PEP with hexose diphosphate. The evidence supports a distinction between supplier-described metabolic applications and published findings on PEP, especially when interpreting inflammation or healthy-aging claims.

• What Lineage Tracing Says About Mouse Neo-Oogenesis

  2026-10-13

  A dual-recombinase lineage-tracing study reports no detectable postnatal generation of new oocytes in mice under physiological conditions or after busulfan-induced ovarian injury. The findings strongly weigh against in vivo neo-oogenesis, while remaining bounded by the sensitivity and specificity of genetic labeling, the injury model, and the limits of extrapolating from mice to humans.

• What the CRC Autophagy–Metastasis Signature Shows

  2026-10-13

  Bai et al. combine bulk and single-cell transcriptomic analyses to derive a six-gene colorectal-cancer risk signature, but its immune and treatment-response implications remain computational associations rather than clinical proof.

• What Lewy Pathology Reveals About Cortical Neurons

  2026-10-12

  A 2024 spatial-transcriptomics study identifies cortical neuron classes associated with Lewy pathology and reports a cross-species molecular signature of dysfunction. The findings are informative but largely correlative, and they should not be conflated with protein-level validation or clinical evidence. The supplied product information for InstaBlue Protein Stain Solution describes a Coomassie Brilliant Blue protein stain for general gel-based visualization, but does not establish that it was used in the cited study.

• IL-15 and CREATE: Evidence Boundaries

  2026-10-12

  An evidence-bounded overview distinguishing supplier-reported Recombinant Human IL-15 characteristics from the proof-of-concept findings and limitations of the CREATE RNA-based gene-editing platform.

• ALC-0159 and the Evidence Chain in mRNA Immunity

  2026-10-11

  ALC-0159 is a PEG-conjugated lipid excipient used in mRNA lipid nanoparticle formulations. This evidence-focused analysis explains what the Grippin study shows about mRNA vaccines and immune checkpoint inhibition—and what it does not establish about any individual excipient.

• I-BET-762: Reading BET–Ferroptosis Evidence

  2026-10-10

  I-BET-762 is a selective BET inhibitor whose reported effects connect epigenetic regulation with ferroptosis, inflammation, and cancer biology. This evidence-focused analysis explains what the 2024 BRD4 study establishes, what remains context-dependent, and how to interpret the compound’s research value.

8199 records 1/547 page Next 12345 下5页 Last page